What question did this study set out to answer?

To outline recent clinical updates in the management of non-small cell lung cancer focusing on targeted therapies, immunotherapies, and biomarker testing.

March 1, 2021Journal of the National Comprehensive Cancer NetworkOpen Access

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

View Full Paper

Ask AI

Bookmark

To outline recent clinical updates in the management of non-small cell lung cancer focusing on targeted therapies, immunotherapies, and biomarker testing.
Expert consensus review by the NCCN panel evaluating emerging clinical evidence for non-small cell lung cancer.
Systematic appraisal of recent therapeutic developments to update standard institutional treatment recommendations.
Incorporated updated guidance for targeted therapeutic agents alongside their corresponding molecular biomarkers.
Refined clinical algorithms regarding the selection and implementation of immunotherapy regimens for eligible patient subgroups.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Clinical practice guideline reveals updated targeted therapy and immunotherapy recommendations for non-small cell lung cancer, highlighting biomarker-driven clinical decision-making.

Cite This Study

Ettinger et al. (2021) studied this question.

synapsesocial.com/papers/69dc05561e0ecb2eb49c7b84 https://doi.org/10.6004/jnccn.2021.0013

View Full Paper

Ask AI

Bookmark

Implication

Clinical practice guideline reveals updated targeted therapy and immunotherapy recommendations for non-small cell lung cancer, highlighting biomarker-driven clinical decision-making.

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

Key Points

Discussion

Implication

Cite This Study

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider